- NewsCategory：
- All Company news Industry news
common83One result
-
1031
Gotham Therapeutics Establishes A ¥→σdvanced Oncology Profiling Cascade <β with ProQinase to Progress its Po♠≤εβrtfolio of Epitranscriptomic Drug Candidates
Gotham Therapeutics Establishes Advanced Oncolog&✔y Profiling Cascade with ProQα★λinase to Progress its Portfolio oε>f Epitranscriptomic D™>rug CandidatesWEDNESDAY, OCTOBER 30,♣∑ 2019Gotham Therapeutics, '✘♣a biotechnology company developing a novel druγ♠g class targeting RNA-modifying proteins, andφ↑ ProQinase, an early stage drug¥∑-discovery company, recently acquired ↑β>by Malvern/PA-based Re ↕¶action Biology Corp., today an★♥≤εnounced that they have establisπ☆♦£hed an array of advanced biochemical and ¶φ→cellular assays to ch₩↓<εaracterize epitranscriptomic-direc←$Ω•ted compounds.“Establishing ta↑βδilored target engagement, cell biology, phenot✔∏ypic, and in-vivo assa↔ys to evaluate compounds origina♠<ting from our three most advanced ep×itranscriptomic programs in p≈€arallel is a crucial n<★×ext step to develop our broad pipel÷ £ine towards the clinicΩλδ,” said Dr. Gerhard Müller, Chief™♦β¥ Scientific Officer of Gotham Therapeutics. “B↔♥y pursuing the full range of the reader-writer$♣ -eraser continuum, we are able t→φ↕→o focus on targets with the most compellinσ g links to disease and adv♠¶ance those programs in tande↕σ÷m.”“Combining our high pr←γ∞oficiency in providing customi¶ zed solutions as early stage drug-disγ>§covery services, including tailor-made bio≠•☆chemical and cell-based assays, with Gotham₩✔’s expertise in epitranscriptomics, we were abl↓≥e to establish in a very short time a set<∏ of customized enzymatic aφλαnd cellular assays for compounds addressing '≠three different mRNA-modifying ta≤≥ rgets,” said Dr. Sebastian Dempe, <•Chief Executive Officer of ProQinase. “We ε> look forward to supporting Gotham as the co↕←✘mpany advances its programs into lead optimi> ♦zation and to continued work wi ¥th the Gotham team as₽®±sisting the company to advance✔¥↓→ its broad pipeline in a time-effe≥₹ ctive manner.”In addition to e∏←&stablishing a tailor-m÷ ade profiling cascade for compounds fro₽€∞✔m its three most advanced progr↔™™£ams, Gotham has also ma↕÷de progress in strengthening its drug discovery<♥ engine and developing its candi♥↓date base. Gotham previously completed the gene-☆≤←to-lead phase for its drug di≠♣☆λscovery project targeting the ME∞λλTTL3/METTL14 complex and esφ₽tablished a robust discovery process as a plat™✘form for future projectλ©s. The company has also generated €☆ε₹a library of high-quality compounds tailor-made✔£¥§ for accelerated hit generation and hit ≥-to-lead expansion agai≈ γnst large parts of the epitranscriptomic targe∑₩"t space. This library includes →÷ •a collection of over 2,000 anal™×≈ogues covering over 80 distinct chemo✔σtypes that will be used to fur≠ther accelerate Gotham’s drug discover"∏↑y efforts as it expaΩγ★nds its pipeline.The original link:https://ww£$∞w.pharmafocusasia.com/ne✘§ws/gotham-therapeutics-establishes-advanced-onco★"logy-profiling-cascade≥ ↑±-with-proqinase-to-progress-its&λ∑-portfolio-of-epitranscriptom♥÷ic-drug-candidates2019 Asia-pacif≥δ ←ic pharma IP Leader Summφ$it: http://en.zenseegroup.com/p/510934/w ¥ill be held in Beijing&n∑♦≈bsp; on November 14-15, and will att∞↔₽ract more than 500 industry exφ"perts from domestic and foreign pharm ♠±aceutical companies, biotechnology compaγ¶nies, governments, associations, law firms, →$¥intellectual property agents ≈↔&and other companies to attend.Off€βicial registration and ★ ®₩consultation channels:'↓©®Contact：AnnPhone: 021-65650305Email：Markeπ↔ ∏ting@zenseegroup.comhttp://en.ze& nseegroup.com/p/510934 -
1030
Gilead and Glympse Bio Announce Strateg↓•ic Collaboration for γ✘Use of Biomarker Technolog×εy in NASH Clinical Development
Gilead and Glympse Bio Announce Strategδβ∞↔ic Collaboration for Use of>÷ Biomarker Technology in NASH Clinical DεΩ←•evelopmentTUESDAY, OCTOBER 29, 2019Gileaφα✔×d Sciences Inc. and Glympse Bi∏<≤o, Inc., today announced that ≈↓the companies have entered int₩♣↓₩o a strategic collaboration ÷♣§↑in nonalcoholic steatohepatitis (NASH §) clinical development. Glympse Bio’s pro$←"prietary synthetic biomarkers – bioengineered to₽€ identify stage and pro§✘♦gression of disease as well as early€©₹★ detection of treatment response – will be used ₩§₹γto determine clinical trial participants’δ÷₩δ stage of disease at initia≤♥l screening and to determine rφ±δ esponses to study trea $tment in Gilead’s NASH©ε clinical program.“We are excited about✘¥ the opportunity to partn™• $er with Glympse Bio to hel↓Ωγp inform our NASH development program,” sai↔÷∑≠d Mani Subramanian, MD, PhD Senior V♣§ice President, Liver Diseases, Gilead Sci ♣"↔ences. “By utilizing this innovative ♥σΩtechnology, we hope to better characterize this∏φ complex disease and imp≤ ₹rove our understanding of how our com±₽pounds impact disease progressio↕≤n.”Glympse Bio’s propr♠ ≠ ietary technology, Glympse Inside™, combines s¶↓ynthetic biomarkers with machine learni↔>±ng approaches to identify the stage and monitor↑✔β$ progression of impoδε™÷rtant, complex diseases such as cancer, fibr→✔osis, inflammation, and inδ×★βfections, in real time.“We are very ♣♠₹excited about partnering with Gilead, a leaderβ★• in drug development, to help drive earlier and m÷εσore favorable outcomes for patients,” said "™•±Caroline J Loew, President and'↕≥£ CEO, Glympse Bio. “Gilead’s commitment to ♦♦developing innovativ©≤e medicines in areas of high unmet medical ↑φ need aligns with our πmission of transformi≈"ng disease detection and measuri↕$γng treatment response, al✔φl with the goal of helping improve ☆✘&the lives of patients.”information↔ source:pharma ±♣focus AsiaThe original link:htt÷ps:https:https://www.pharmafocusasia.coΩβ>m/news/gilead-and-glympse-bi↕♥o-announce-strategic-collaboration-for-use-of-✘®λ¥biomarker-technology-in-nash-clini₩π∞cal-development2019 Asia-pacific pharma IP Leadeε₩'r Summit:http://en.z✘'™←enseegroup.com/p/510934/ will be ↑< held in Beijing on&nbs€ p;November 14-15, and will£™≤↑ attract more than 500 industry experts from dom→σ'estic and foreign pharmaceutical c₽<ompanies, biotechnology companies, governments, ¥↔associations, law firms, intellectσπual property agents and othe$α±r companies to attend.Official regi®≠€γstration and consulta∑→tion channels:Contact： AnnPhone: 021-6565030≤"5Email：Marketing@zenseegroup.comhttp:/∏₽/en.zenseegroup.com/p/510934 -
1029
HistoIndex Announces Glo∞σ<€bal Partnerships To Expand '§AI-Based Digital Pathology Platform
HistoIndex Announces↔♥∞₹ Global Partnerships To Expand AI-Based∏ π∏ Digital Pathology PlatformMONDAY, OCTOBER♥ 28, 2019HistoIndex an♠¶nounces the expansion of its AI-based digita∏©Ωl pathology platform towards largφ e-scale NASH preclinical '®programs for pharmaceutical and biotech co↑≥ mpanies to achieve quantifiable and reprodu'≤cible data on therapeutic respλ↓>onses in NASH animal mα§odels, and to aid CROs as well as research age ¶©✔ncies in validating new models mimicking'×δ♥ the NASH disease.Published preclinica↔" l studies have demonstrated the use of HistoInσβ≠dex's fully quantifiable Second Harmonic Generat© β"ion (SHG) technology as a highly accurate st ↔≥ain-free method that ☆can monitor the efficacy of various tδφherapeutic agents, by quantiε$∞δfying more than 450 NASH-associated parameters∏σ in fibrosis, inflammation✔₽₩Ω, ballooning and steatosis. The iΩ¶nformation of these NASH-associated par∑ ameters gathered from ∞₩the entire liver tissue∑α♦, provides comprehensive insight•±≥≠s on the mechanism of action of the therapeu ↕&♥tic agent. As a drug discovery tooσ₽≠l, HistoIndex's SHG-enabled digital← ¶ pathology platform wil ™ l allow pharmaceutical and biotech comו↑&panies to select promising lead candidates for→↔&∞ further optimization and make α★informed decisions in the management of their ®δNASH drug development pipeline.In addition to o♥↓§ngoing NASH clinical trπials, HistoIndex is currently involved ₽in multiple preclinical stε≤udies, most of which are conducπ↑ γted by major pharmaceutical and bi"≈ otech companies, medical un™£iversities, CROs and researcγπh agencies. Notably,★'β HistoIndex has recently entered into a collaborπ™ation with the A*STAR's≠§ Genome Institute of Singapore™♣ (GIS) to validate their in•' vivo and in vitro NASH models based on Asian<₽-centric clinical data. Says P>♦rofessor Patrick Tan♣≠✔, Executive Director o☆ β↔f the Genome Institute of Singapore (GIS), "§<®✘At GIS, we conduct our preclinica₩♦l studies on fatty liver involving data from ani↑Ω±mal models based on pα∞↔γatient-derived transcr®♦iptomic data. This has a ♥" £high translational potential as it helps us to pi≠¥™npoint new therapeutic targets and their★≤ validation. Therefore, using a fully quantita↓♦tive, reliable and ob$↑×&jective pathological evaluation such as HistoIndα>ex's AI-based digital pathology platform is esseΩ<<☆ntial to the success♠¶↑ of our efforts in therapeutic target discovery."¶≤$£HistoIndex is also a partner with <λ↔±globally-renowned CRO, <✔WuXi Apptec, in advancing t>§heir NASH preclinical progra∞←ms with advanced R&D and smart imagi♦≤ng analysis capabilities. Publi≠£shed study data will b¶™§↓e available for discussions during↕ networking opportunities thr♥&"εoughout AASLD's The Liver Meeting® in November 2✘≠↕≥019. "We are very excited to ext>↕ λend our AI-based SHG platform to pr∞♠γeclinical studies to help companies with drug diα®scovery programs select promisiλβ∏ng lead candidates for fur≥ther optimization and subsequent clinical☆γ development," says Dr Poon Thon←✔g Yuen, Chief Executive Officer ∞ ®of HistoIndex. "Our SHG image analysis platform ↑•has already been used to analyze the efficacy₹&&♣ of a series of promising drug∑≤© candidates for NASH within various animal €¥models commonly-used by the industry, a♥♣✔nd we believe these preclinical partnership€€Ω∞s will help drive the adoption of our★ platform significantly."informa'₽¥tion source:pharma focus AsiaTh≥↕∏e original link:https:α≤®$https://www.pharmafocus∑←asia.com/news/histoindex-announces-global-partnerε₩ships-to-expand-ai-based-digital-pathology-pla>§÷tform2019 Asia-pacific pharma IδP Leader Summit: http:α↕♦//en.zenseegroup.com/p/510934/will be held i♥↔n Beijing on Novembe→σr 14-15, and will attract more than 500 in÷♥dustry experts from domestic × &and foreign pharmaceutical companΩ₹ies, biotechnology compani₹$∑↑es, governments, associations, law firms, intell→™₹ectual property agents and other companies toα→≠ attend.Official registration and consultλ ₩ ation channels:Contact：AnnPhone: 021-65650305E₽←mail：Marketing@zenseegroup.comhttp://en₩↕.zenseegroup.com/p/510934 -
1028
AVROBIO Receives Orphan-Drug Designatγ★ion from the U.S. FDA for AVR‑R♦Ω¥D‑02 for the Treatment of Gaucher Dise∏≈"ase
AVROBIO Receives Orphan-Drug Designati$↕¥↑on from the U.S. FDA for AVR‑RD‑02 for the Treatm>¶ent of Gaucher DiseaseFRIDAY, OCTOBER 25, 2019♦↔&♠AVROBIO, Inc., today announced that th♣>↓✘e U.S. Food and Drug Administration ( λFDA) has granted orphan-drug d←∑esignation for the Company’s investigat≥✘↔∏ional gene therapy, AVR-RD-02, € ←>for the treatment of Gaucher disease. AV≠∑♦ R-RD-02 consists of the patienγ✔∞<t’s own hematopoietic ♦÷∞stem cells, genetically modi₽÷≥♥fied to express glucocerebrosidas♦±e (GCase), the enzyme that is deficie₹α×←nt in Gaucher disease. Thφ↓λ¶e Company is actively recruiting in Canadφδ₹≈a for its Phase 1/2 clinical trial of AVR-RD¥₹₹ε-02, which seeks to evaluate the safety and effi↑ cacy of the therapy in patients wit★ h Type 1 Gaucher disease.“Under the existing st♥≈andard of care, patients with Gaucher disease≈≥₹ are bound to a lifelongδ® ≈ infusion schedule of enzyme replacemen←♠>t therapies, and still₹← experience painful and progressive sympto♥♥↓$ms such as debilitating musculoskel♣πλ✔etal pain and fatigue,” said☆$₽ Birgitte Volck, MD, PhD, President of Research a∑&nd Development at AVROBIO. “Orphan-drug desig™∏±nation recognizes the unmet need of populations←¶ with rare diseases like Gaucher where AVROB∏✘©λIO strives to transform lives by adβφdressing the underlying cause of the disease w±αith a single dose of gene therapy.”Orphan-d"&♦rug designation is granted by the FDA t♣σo drugs and biologics which are inten₹φ₹ ded for the safe and effective πtreatment, diagnosis or prevention of rare diseas₹×™es or conditions that affect fewer than 200 ₹§,000 people in the United States. Orphan₽π☆✔-drug designation provide≤α♥s certain incentives, which may include ta ₽x credits towards the cost of clinical t≠×rials and prescription drug user fee waivers.info€×Ωrmation source:pharma focus A←✔siaThe original link:https✔∑∑×:https://www.pharmafocusa±∑$sia.com/news/avrobio-receives-orpha↔n-drug-designation-from-the-≥©βus-fda-for-avrrd02-for-ε♠the-treatment-of-gaucher-disease2019≥∑€ Asia-pacific pharma IP Leader Summit: http:$₽//en.zenseegroup.com/p/510934/will be hel₽ σ♦d in Beijing&nb→•sp; on November 14-15, and will attrac★>•♥t more than 500 industry experts from domestic a¥¶nd foreign pharmaceuti©↑cal companies, biotechnologyφΩΩ companies, governments, associatioσns, law firms, intellectual property ÷€agents and other companies Ω>←♦to attend.Official registration a$¥←nd consultation channels:Conta☆§$∑ct：AnnPhone: 021-65650305Email：Marketing@z☆♠¶•enseegroup.comhttp://en.zenseeg↓↕<roup.com/p/510934 -
1026
AZTherapies Strengthens Neuroinflamδ'≠mation-Targeted Pipeline Th≈↑rough Acquisition of Smith Therapeutics
FRIDAY, OCTOBER 25, 2019AZ≤✘Therapies, Inc., a biopharmaceutical comp↔♣<any developing therapeutics to extend br₽€®≤ain health, today announced the a♠$₽<cquisition of Smith Therapeutics, a private bi'γ<opharmaceutical company with a shared goal of"÷ ¶ targeting neuroinflam↑↓™≠mation to treat neurodegenerative disease. Smit¥↔±h Therapeutics’ Found ₽♥♥er and Chief Executive Officer Philip Ashto∑$±n-Rickardt, Ph.D., has joi☆•§ned the senior leadership team at AZThera&✘∞pies as Senior Vice President of ¥→÷Immunology. Financial terms of the acquisitio &♥n were not disclosed.±≥ Smith Therapeutics’ proprietary resΩαearch platform focuseΩ↑≈♦s on the use of modified T cells to restor€ φ¥e a healthy balance of inflammatory and reg→€✔πulatory cells in the brain. To date× , Smith has successfully engineered ₹Ω immunosuppressive T regulatory ↑®↑(Treg) cells with Chimeric Antigen Recε↓αeptors (CARs) targeting®₹Ω brain glial cells. Previous research has dα∑emonstrated the ability of Tregs to ★↑π¥dampen microglial activity and reduceφ™≈ neuroinflammation in models of neurode£&α®generation, suggesting the•₽ir potential utility in the treatment of dise•↔<&ases including Progreδ ↔ssive Supranuclear Palsy (PS÷<♦P), Alzheimer’s disease, Parε↓↓¶kinson’s disease, Huntington’s dβδ₹isease, Amyotrophic Later☆↔₩™al Sclerosis (ALS), an×™d others.“This acquisition repε≠£resents a meaningful step fo£'✘rward for us as we continue to strengthen our leaπ★€₩dership position in the development of the≤δrapies targeting neuroinf ↔lammation to stop or slow♦ the progression of neurodegenerative diseases₩λ≥,” said David R. Elmaleh,™♦• Ph.D., Founder, CEO, and Chairman of AZThera®↑Ω₩pies. “We are excited to be workin&€&£g with Philip as we add this cutting-edge techα☆<€nology to our portfolio♦ of innovative programs. An esteemed i≥≈ mmunologist and inventor♣ ₩ of the technology, Philip brings unp↓☆©↔aralleled expertise to the compβ any and we look forward to a✔•≈dvancing this CAR-Tre ☆λ✘g program further into IND-enabling studies anΩ →®d into clinical development as$ rapidly as possible.←λ”Dr. Ashton-Rickardt commented on the acquisitionεφ and his appointment: “Our shaσ∑©βred rationale of targeting neuroinflammation as ¥&§the root cause of neurodegene>₽≈rative disease makes this acquisition a gλβ÷∑reat strategic fit f₩♥or us. With AZTherapies’ e₩≈xpertise in drug development and clinical trial e₩∞xecution, we believe that together, we are we$✘ll positioned to advance&δ our CAR-Treg technology and f&σundamentally change ©'©neurodegenerative disπ☆γease progression.”Prior t≠₩o launching Smith Therapeutic≤¶ &s in 2017, Dr. Ashton-Rickardt was±₹& Chair in Immunology at Imperial Colleg÷π↔e London, Visiting P§ σrofessor, Brigham and Wom₩αen’s Hospital, Harvaδ☆rd Medical School, and Associaε↔te Professor in the Department of Pathology atσφ★δ the University of Chicago. His work has bee§↔αn recognized by his pe→★♦ers through the award of teε♥∏nure from The University®× of Chicago and by his fellow citizens as a reci↑© pient of the Early Career Award for Scientists anε♦σd Engineers from Presid$↕↔ent Bill Clinton. He has published $"₹more than 65 peer-revie↕↑₹λwed papers in more than 30 acad∞ emic journals (including Cell, Science, Im≈Ωσmunity, and Nature Immunology), has÷Ω↓ served as an editor &₽for several academic journals, and ha↓∏s been a member of grant review boards globally&π₹. Dr. Ashton-Rickardt received a B.Sc. in Bio♠♣÷Ωchemistry from the University of πLondon, King’s College§÷✔¶ with honors, a Ph.D. in Molecular Biology from ×₩the University of Edinburgh, aε> nd completed post-docto£☆•♠ral work at the Univer<✔∞sity of Edinburgh and t₽'δhe Massachusetts Institute of Technology in Mol$★ecular Biology and Molecular Immunology, respectiαδvely.information source:pharma focu¥♥≤φs AsiaThe original link:h₽→$δttps:https://www.pharmafocusasia.com/news/azthe→¶rapies-strengthens-neuroinflammation-t±&←argeted-pipeline-through-acquisition-of-smith>€∏-therapeutics2019 Asia♣§-pacific pharma IP Leader Summit: http://en.zen→ seegroup.com/p/510934/will be©® held in Beijing on ↕♦®$;November 14-15, and will attract more than 5∑¶00 industry experts from domestic α§σ$and foreign pharmaceutical c♠δ←ompanies, biotechnology companies, govern¥₹ments, associations, law firms, intelle"ctual property agents and other comp₩ $anies to attend.Official registration and∞♠ consultation channe≠&λφls:Contact：AnnPhone: 021-65650305Email：Mark₽÷eting@zenseegroup.comhttp://en.z±enseegroup.com/p/510934
Contact Us
Zensee_Daystar online
© 2011-2016